Psoriatic Disease

A university psoriatic arthritis center focusing on close collaboration between rheumatologists and dermatologists helped significantly decrease time to diagnosis, according to data published in BMC Rheumatology.

Hospitalizations for sepsis, skin and soft tissue infections and UTI among patients with psoriatic arthritis “significantly” decreased over a 5-year period despite a rising uptake in biologics, according to data presented at ACR Convergence 2021.

Risankizumab provides statistically greater improvements in signs and symptoms relative to placebo, and is well tolerated among patients with psoriatic arthritis, according to data presented at ACR Convergence 2021.

Among patients treated with TNF inhibitors, the risk for serious infection was “significantly lower” in those with psoriatic arthritis compared with rheumatoid arthritis, according to data published in the Annals of the Rheumatic Diseases.

Physical activity can lead to improved quality of life and self-reported function in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis, according to data published in Arthritis Care & Research.

Treat-to-target tapering of TNF inhibitors in patients with psoriatic arthritis or axial spondyloarthritis does not result in any negative impact on disease activity, compared with the full dose, according to data published in Rheumatology.

Patients with psoriasis who use biologics are more likely to develop psoriatic arthritis than those on other or no therapies, according to retrospective data published in the Annals of the Rheumatic Diseases.

Diagnoses of arthritis, axial symptoms and tendonitis or enthesitis often increase over time before a patient is finally diagnosed with psoriatic arthritis, according to data published in Arthritis Research & Therapy.

Patients with psoriatic arthritis prefer oral over subcutaneous biologics, and prioritize complication avoidance and the ability to work and perform ordinary activities over clinical efficacy, according to data.

Patient reported data from two phase 3 trials found roflumilast cream 0.3% significantly reduced itch severity and impact in psoriasis patients, according to a presentation at the EADV Congress virtual meeting.